Satralizumab
BN40900
Phase 3 small_molecule completed
Quick answer
Satralizumab for Neuromyelitis Optica (NMO) is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Neuromyelitis Optica (NMO)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed